Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3news2026-08-06T06:56:05+00:00August 6th, 2026|Endpoints News|
FDA approves Moderna flu vaccine after spat with past agency leadersnews2026-08-06T02:25:52+00:00August 6th, 2026|Endpoints News|
Revolution Medicines preps for launching pancreatic cancer drug, ups 2026 expensesnews2026-08-06T01:31:29+00:00August 6th, 2026|Endpoints News|
FDA approves Takeda’s orexin drug for narcolepsynews2026-08-05T21:33:01+00:00August 5th, 2026|Endpoints News|
Senate confirms Erica Schwartz as CDC directornews2026-08-05T19:49:17+00:00August 5th, 2026|Endpoints News|
Atossa Therapeutics founder to be selected as NIAID director — reportnews2026-08-05T18:16:00+00:00August 5th, 2026|Endpoints News|
Demis Hassabis ‘leaning into’ Isomorphic CEO role amid Alphabet’s AI shakeupnews2026-08-05T18:11:04+00:00August 5th, 2026|Endpoints News|
In a first, WuXi AppTec surpasses Lonza’s six-month revenue news2026-08-05T17:59:02+00:00August 5th, 2026|Endpoints News|
Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offeringnews2026-08-05T14:28:57+00:00August 5th, 2026|Endpoints News|
Merger talks between AstraZeneca, Bristol Myers are off — reportnews2026-08-05T12:44:58+00:00August 5th, 2026|Endpoints News|
